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Trajectories of metabolic risk factors and biochemical markers
prior to the onset of type 2 diabetes: the population-based
longitudinal Doetinchem study
G Hulsegge1,2, AMW Spijkerman1, YT van der Schouw2, SJL Bakker3, RT Gansevoort3, HA Smit2 and WMM Verschuren1,2
BACKGROUND: Risk factors often develop at young age and are maintained over time, but it is not fully understood how risk
factors develop over time preceding type 2 diabetes. We examined how levels and trajectories of metabolic risk factors and
biochemical markers prior to diagnosis differ between persons with and without type 2 diabetes over 15–20 years.
METHODS: A total of 355 incident type 2 diabetes cases (285 self-reported, 70 with random glucose ⩾ 11.1 mmol l− 1) and 2130
controls were identiﬁed in a prospective cohort between 1987–2012. Risk factors were measured at 5-year intervals. Trajectories
preceding case ascertainment were analysed using generalised estimating equations.
RESULTS: Among participants with a 21-year follow-up period, those with type 2 diabetes had higher levels of metabolic risk
factors and biochemical markers 15–20 years before case ascertainment. Subsequent trajectories were more unfavourable in
participants with type 2 diabetes for body mass index (BMI), HDL cholesterol and glucose (Po0.01), and to a lesser extent for waist
circumference, diastolic and systolic blood pressure, triglycerides, alanine aminotransferase, gamma glutamyltransferase, C-reactive
protein, uric acid and estimated glomerular ﬁltration rate compared with participants without type 2 diabetes. Among persons with
type 2 diabetes, BMI increased by 5–8% over 15 years, whereas the increase among persons without type 2 diabetes was 0–2%
(Po0.01). The observed differences in trajectories of metabolic risk factors and biochemical markers were largely attenuated after
inclusion of BMI in the models. Results were similar for men and women.
CONCLUSIONS: Participants with diabetes had more unfavourable levels of metabolic risk factors and biochemical markers already
15–20 years before diagnosis and worse subsequent trajectories than others. Our results highlight the need, in particular, for
maintenance of a healthy weight from young adulthood onwards for diabetes prevention.
Nutrition & Diabetes (2017) 7, e270; doi:10.1038/nutd.2017.23; published online 8 May 2017
INTRODUCTION
Although it has been well established that adverse levels of risk
factors often develop early in life and are maintained over time,1–6
it is not fully understood how they progress to type 2 diabetes
(T2D). For example, T2D might be preceded by a gradual
accumulation of the adverse effects of risk factors starting at a
young age, or by a relatively sudden deterioration in risk factors
before disease onset, or by a combination of both. The
comparison of long-term trajectories of risk factors between those
who do and those who do not develop T2D may help to identify
at which time point these trajectories start to deviate before the
development of overt disease. Such insight into the timing and
the extent of pathophysiological changes before symptoms occur
may provide indications for the optimal timing of preventive
actions. Trajectories of BMI and waist circumference are of
particular importance since these are strong modiﬁable risk
factors of T2D.7,8 Other relevant factors associated with T2D
include glucose levels,9 β-cell function,10 insulin resistance,10
blood pressure,8 lipids,8 liver fat markers,11,12 markers of chronic
inﬂammation13 and kidney function.14
Several studies have described gradual changes in β-cell
function, insulin resistance, fasting glucose and 2-h post-load
glucose many years before diagnosis of T2D with steeper
unfavourable changes 3–5 years before diagnosis.15–19 Only a
few studies, mainly among men, have examined progressive
changes of other risk factors, such as BMI, but so far ﬁndings have
been inconsistent. The Whitehall II study showed that adults who
developed T2D had similar trajectories of BMI and C-reactive
protein (CRP) but more unfavourable trajectories of systolic blood
pressure and high-density lipoprotein (HDL) cholesterol compared
with adults without T2D, over a period of ~ 14 years.20,21 In
contrast, a small study of 177 men observed larger changes in BMI,
but no differences in blood pressure, HDL cholesterol and liver fat
markers in men who developed impaired fasting glucose
compared with men who did not, over a 9-year period.22
A short-term study (that is, over 1.5 years) observed differences
in changes of alanine aminotransferase (ALT) and triglycerides but
not in blood pressure, total cholesterol and HDL cholesterol
between high-risk men with incident T2D and controls.17
A longer follow-up period in a population-based study and
inclusion of other metabolic risk factors and biochemical markers
is needed for more insight in the physiological changes preceding
the onset of T2D. There is also a need to investigate differences
between men and women since previous studies reported several
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sex-related differences in the associations of risk factors such as
systolic blood pressure, HDL cholesterol and uric acid with
T2D.23,24 Therefore, we examined whether trajectories of meta-
bolic risk factors and biochemical markers among initially healthy
men and women differed for those who developed T2D and those
who did not over a period of up to 15–20 years.
MATERIALS AND METHODS
Population
The Doetinchem Cohort Study is a population-based longitudinal study
of men and women aged 20–59 from Doetinchem, a town in the
Netherlands. Men and women were invited for a clinical examination in
1987–1991 (wave 1, N=7 768, participation rate: 62%), 1993–1997 (wave
two, N=6 117), 1998–2002 (wave 3, N= 4 918), 2003–2007 (wave 4, N= 4
520) and 2008–2012 (wave 5, N=4018). Response rates were 75% or
higher in waves 2–5. Details of the study are described elsewhere.25
Exclusion criteria were participation in only one wave (N= 1 378); prevalent
diabetes at baseline (N= 48); missing diabetes status in all waves (N=3)
and the missing data on biochemical markers in all waves due to absence
of informed consent to use blood samples for future research (N=122).
This led to a population of 2913 men and 3304 women. Pregnant women
were excluded for the wave in which they were pregnant. All participants
gave written informed consent in each wave and the study was approved
by the Medical Ethics Committee of the University Medical Center Utrecht.
Measurements
Weight, height, waist circumference, diastolic and systolic blood pressure
measurements, and blood samples were taken according to standard
protocols.25 Total cholesterol and HDL cholesterol were measured until
1998 in non-fasting EDTA-plasma and from 1998 onwards in serum, using
standardised enzymatic methods. In 2013–2014, standardised enzymatic
methods were used to retrospectively determine triglycerides, ALT, gamma
glutamyltransferase (GGT), high sensitivity CRP, uric acid, cystatin C and
creatinine levels of waves 2–5 for the whole population using blood
plasma that had been stored in freezers. Details of all measurements are
described in the Supplementary Material. Estimated glomerular ﬁltration
rate (eGFR) was calculated using the combination of cystatin C and
creatinine.26 The data on educational attainment, smoking status and use
of anti-hypertensive and cholesterol-lowering medications were obtained
by questionnaire.
Type 2 diabetes
T2D was ascertained by self-report. Of the self-reported cases up to 31
December 2007, 80% were checked with the general practitioner or
pharmacist registries (N= 201):27 176 of these 201 self-reported cases were
conﬁrmed as having T2D. All self-reported incident diabetes cases that
were not checked (N= 109) were considered to have type 2. In addition, 70
participants were ascertained as having incident T2D by a measurement of
random glucose of ⩾ 11.1 mmol/l in the physical examination for our
study. This gives a total of 355 participants with incident T2D.
Selection of controls
For each incident T2D case (N= 355), six controls were randomly selected
from the same study wave and matched on age (±2 years) and sex using
incidence density sampling, the preferred method for a nested case-
control design and recently proposed for retrospective, longitudinal
analyses.28,29 We performed age, sex and wave matching to limit the
possibility that differences in risk factors due to differences in age and
length of follow-up would obscure the differences in risk factors between
participants with and without T2D.
Data analysis
The time of case ascertainment was the ﬁrst examination wave in which
participants reported that they had T2D and/or were found to have a
random glucose ⩾ 11.1 mmol l− 1. The same wave was used for their
matched controls. Participants were followed back in time for 6–21 years,
depending on the wave in which they were ascertained as being a T2D
case or control (Supplementary Figure 1), that is, participants ascertained
in waves 2, 3, 4 or 5 could be followed back in time for 6, 11, 16 or 21 years,
respectively. BMI, blood pressure, total cholesterol and HDL cholesterol
were followed back in time for a maximum of 21 years. Other risk
factors were followed back in time for a maximum of 15 years since those
factors were not measured in the ﬁrst examination wave.
Trajectories preceding case ascertainment were constructed by estimat-
ing the marginal means based on the parameter estimates at four or ﬁve
points in time using linear generalised estimating equation models with an
autoregressive correlation structure, separately for each risk factor and
marker (dependent variable). T2D status was included as an independent
variable in the model to obtain trajectories separately for participants with
and without T2D. The model also included the following independent
variables: linear, quadratic and cubic terms of age, examination wave, and
time as a categorical variable (that is, examination wave). The analyses
were stratiﬁed by sex. Age was centred at 60 years, which was
approximately the mean age at wave 5, and examination wave was
centred at wave 5 to ﬁt trajectories for a hypothetical population of 60 year
olds in 2008–2012 (T0). Trajectories of diastolic and systolic blood pressure
were also adjusted for anti-hypertensive medications, and trajectories of
total cholesterol, HDL cholesterol and triglycerides for cholesterol-lowering
medications. We log-transformed triglycerides, ALT, GGT and CRP and
reported geometric means since these biochemical markers did not have a
normal distribution.
For participants with a self-reported diagnosis, the date of diagnosis was
somewhere between the ﬁrst wave in which they reported that they had
T2D (case ascertainment) and the previous wave. Treatment after diagnosis
(that took place in between two successive waves of our study) may have
changed the trajectories of participants with a self-reported diagnosis, and
would be reﬂected in the trajectory over the last 5 years before case
ascertainment. Therefore, the trajectory over the last 5 years was not taken
into account when testing differences between those with and without
T2D in the total trajectories of metabolic risk factors and biochemical
markers. The time from 15/20 years prior to case ascertainment up to 5
years prior to case ascertainment was used to statistically test differences.
This was done using an interaction term for the interaction between the
independent variables T2D status and time (dummy relating T− 15/− 20 to
T− 5), assuming a linear pattern over that period. Differences in trajectories
of risk factors and biochemical markers between participants with and
without T2D during the last 5 years prior to case ascertainment were also
tested using an interaction term between T2D status and time (dummy
relating T− 5 to T0). A Po0.10 was considered statistically signiﬁcant for
interactions. The analyses were also stratiﬁed by method of case
ascertainment (that is, self-report and random glucose ⩾ 11.1 mmol l− 1)
to further investigate the potential effects of medical treatment after the
diagnosis of T2D among the self-reported cases during the 5 years
preceding case ascertainment. This stratiﬁcation was done for BMI, systolic
blood pressure, total cholesterol and glucose in men. We statistically tested
these differences in trajectories by method of case ascertainment using
interaction terms between time and method of case ascertainment. To
investigate whether differences in trajectories between participants with
and without T2D could be explained by BMI, trajectories were additionally
adjusted for BMI and centred at 25 kg m− 2 in sensitivity analyses. To
investigate potential misclassiﬁcation of controls with high random
glucose levels, we conducted sensitivity analyses in which we excluded
controls with random glucose between 7.0–11.1 mmol l− 1. All analyses
were performed using SAS 9.3 software (Cary, North Carolina, USA).
RESULTS
In total, 194 men and 161 women developed T2D. In participants
with and without T2D, blood pressure, total cholesterol, HDL
cholesterol and BMI were followed back in time for an average of
14.0 years, while the other risk factors and biochemical markers
were followed back for an average of 10.6 years. At case
ascertainment (T0), the average age was 60.5 (range: 34–80) for
men and 61.2 (range: 33–80) for women. Participants with incident
T2D were more likely to have a low level of educational
attainment and to be on anti-hypertensive and cholesterol-
lowering medication (Table 1).
Levels of metabolic risk factors and biochemical markers
15–20 years prior to diagnosis
Among those with a 21-year follow-up period, participants with
T2D had more unfavourable levels of BMI, diastolic and systolic
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blood pressure, total cholesterol and HDL cholesterol than those
without T2D at 20 years prior to case ascertainment (Figures 1a–e,
Supplementary Tables 1–2). Among the same participants, at 15
years prior to case ascertainment, levels of other metabolic risk
factors and biochemical markers were similar (and eGFR) or higher
(glucose, waist circumference, triglycerides, ALT, GGT, CRP and uric
acid) among subjects with T2D than among subjects without T2D
(Figures 1f–m, Supplementary Tables 1–2).
Trajectories
As regards the development in metabolic risk factors and
biochemical markers during the 15–20 years prior to case
ascertainment, those subjects with incident T2D had in particular
larger unfavourable changes over time (that is, unfavourable
trajectories) in BMI, HDL cholesterol and random glucose (P for
interactiono0.01) (Figure 1, Tables 2 and 3). For example, BMI
increased among men and women with T2D with 1.5 kg m− 2 (5%)
(95% CI: 0.9–2.2) and 2.2 kg m− 2 (8%) (95% CI: 1.3–3.1),
respectively, between T− 20 and T− 5. In contrast, among those
without T2D BMI remained stable over time (P40.05). Trajectories
of diastolic and systolic blood pressure, waist circumference,
triglycerides, ALT, GGT and CRP were also more unfavourable in
participants with T2D than in those without T2D, although the
difference was not statistically signiﬁcant for triglycerides, ALT,
GGT and CRP. For example, GGT increased borderline signiﬁcantly
with 0.12 log mg l− 1 (13%) (95% CI: − 0.004 to 0.25) among men
with T2D and non-signiﬁcantly with 0.05 log mg l− 1 (5%) (95% CI:
− 0.02 to 0.13) among men without T2D between T− 15 and T− 5.
During the last 5 years before case ascertainment, levels of
metabolic risk factors and biochemical markers remained stable or
decreased, except for glucose in both sexes and CRP in men.
Trajectories of uric acid and eGFR (that is, declining eGFR) were
more unfavourable for women with incident T2D than for women
without T2D up to 5 years prior to case ascertainment (P for
interactiono0.05), whereas there was no signiﬁcant difference
among men (P for interaction⩾ 0.10). Trajectories of total
cholesterol were not signiﬁcantly different between participants
with and without incident T2D (P for interaction⩾ 0.10) (Figure 1,
Tables 2 and 3).
Differences in trajectories between cases ascertained by self-
report and by random glucose
Trajectories of BMI, systolic blood pressure, total cholesterol and
random glucose were similar for participants ascertained by
self-report and those ascertained by elevated random glucose up
to 5 years prior to case ascertainment (P for interaction X0.10)
(Figure 2). In contrast, during the last 5 years prior to case
ascertainment, levels of BMI, systolic blood pressure and total
cholesterol decreased among participants with self-reported T2D
but not among participants diagnosed by elevated random
glucose based on our study examination (P for interactiono0.10).
Adjustment for BMI
Adjustment for BMI strongly attenuated differences in trajectories
between participants with and without incident T2D for all
metabolic risk factors and biochemical markers except for random
glucose (Supplementary Figure 2).











Age (years), mean (s.d.) 60.4 (8.8) 60.5 (8.9) 61.2 (8.6) 61.2 (8.7)
Educational attainment
Low (%)a 104 (54%) 531 (46%) 119 (74%) 630 (65%)
Smoking status
Current smoker (%) 38 (20%) 217 (19%) 61 (39%) 183 (19%)
Ex-smoker (%) 118 (61%) 651 (56%) 35 (22%) 369 (38%)
Medication
Anti-hypertensive medication (%) 78 (40%) 201 (17%) 86 (54%) 212 (22%)
Cholesterol-lowering medication (%) 68 (35%) 139 (12%) 64 (40%) 98 (10%)
Risk factors and biochemical markers
BMI (kg/m2), mean (s.d.) 29.6 (4.3) 26.6 (3.2) 30.3 (5.6) 26.5 (4.4)
DBP (mm Hg), mean (s.d.) 84 (11) 83 (10) 80 (9) 81 (10)
SBP (mm Hg), mean (s.d.) 142 (18) 135 (17) 135 (19) 133 (19)
TC (mmol l− 1), mean (s.d.) 5.2 (1.2) 5.6 (1.0) 5.5 (1.1) 5.9 (1.1)
HDLc (mmol l− 1), mean (s.d.) 1.09 (0.31) 1.24 (0.33) 1.33 (0.39) 1.56 (0.39)
Random glucose (mmol l− 1), mean (s.d.) 9.5 (3.7) 5.4 (1.1) 8.0 (4.3) 5.2 (0.9)
WC (cm), mean (s.d.) 109 (11) 100 (9) 103 (13) 92 (11)
TG (mmol l− 1), median (IQR) 1.9 (1.3–2.7) 1.5 (1.1–2.1) 1.8 (1.4–2.4) 1.3 (1.0–1.7)
ALT (U l− 1), median (IQR) 22 (17–32) 18 (14–23) 19 (15–23) 15 (12–19)
GGT (U l− 1), median (IQR) 36 (25–60) 26 (20–39) 25 (17–37) 17 (13–25)
CRP (mg l− 1), median (IQR) 2.1 (1.1–3.9) 1.2 (0.6–2.5) 2.2 (1.1–4.6) 1.3 (0.6–2.5)
UA (mmol l− 1), mean (s.d.) 0.34 (0.08) 0.34 (0.07) 0.30 (0.07) 0.27 (0.07)
eGFR (ml min− 1/1.73 m2), mean (s.d.) 92 (18) 89 (16) 87 (20) 87 (15)
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular
ﬁltration rate; GGT, gamma glutamyltransferase; HDLc, high-density lipoprotein cholesterol; IQR, interquartile range; SBP, systolic blood pressure; T2D, type 2
diabetes; TC, total cholesterol; TG, triglycerides; UA, uric acid; WC, waist circumference. aIntermediate secondary education or less.
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Sensitivity analyses
In sensitivity analyses, exclusion of controls with random glucose
levels between 7.0–11.1 mmol l− 1 resulted in the same ﬁndings as
our primary results.
DISCUSSION
Men and women with incident T2D had more unfavourable
levels of metabolic risk factors and biochemical markers than
those without T2D 15–20 years prior to diagnosis. Subsequent
trajectories were also more unfavourable in participants with T2D
than in those without T2D for BMI, HDL cholesterol, glucose and to
a lesser extent for diastolic and systolic blood pressure, waist
circumference, triglycerides, markers of liver fat and chronic
inﬂammation, uric acid and kidney function. The patterns were
similar for men and women. Differences in trajectories between
participants with and without T2D were much smaller after
adjustment for BMI.
A greater decrease in metabolic risk factors and biochemical
markers in those with T2D than in controls during the 5 year prior
to ascertainment was observed. Since the diagnosis of T2D
Figure 1. Trajectories of body mass index (a), diastolic blood pressure (b), systolic blood pressure (c), total cholesterol (d), HDL cholesterol (e),
random glucose (f), waist circumference (g), triglycerides (h), alanine aminotransferase (i), gamma glutamyltransferase (j), C-reactive protein
(k), Uric acid (l) and estimated glomerular ﬁltration rate (m) of those with (solid lines) and without (dashed lines) incident type 2 diabetes.
Geometric means are shown for triglycerides, alanine aminotransferase, gamma glutamyltransferase and C-reactive protein. ALT, alanine
aminotransferase; eGFR, estimated glomerular ﬁltration rate; GGT, gamma glutamyltransferase.
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occurred at an unknown time point during the 5 years preceding
case ascertainment, medical treatment and lifestyle changes will
have often already started before the wave in which a respondent
reported a diagnosis of T2D. This implies that medical treatment
and lifestyle intervention after the diagnosis of T2D had a large
favourable impact on levels of almost all metabolic risk factors and
biochemical markers. This is supported by analyses stratiﬁed by
method of case ascertainment, which showed that the drop in
BMI, systolic blood pressure and total cholesterol was only
apparent in men with a self-reported diagnosis (diagnosed in
the years before case ascertainment), and not in cases ascertained
by elevated random glucose levels during the examination for
our study.
Extending earlier ﬁndings that unfavourable changes in ALT and
triglycerides precede the diagnosis of T2D in men over a 1.5-year
period,17 we showed that differences in ALT, triglycerides and
additionally GGT between men and women with and without
incident T2D already exist 10–15 years before the onset of T2D.
These differences continue to increase until diagnosis, although
no longer at a statistically signiﬁcantly more unfavourable rate in
persons with T2D than in persons without T2D. The increase in
ALT and GGT, indicating hepatic fat accumulation, leads to higher
concentrations of very low density lipoprotein (VLDL) particles in
the circulation, which may lead to hypertriglyceridemia and lower
HDL cholesterol.30 This is consistent with our observed unfavour-
able trajectories in triglycerides and HDL cholesterol that occurred
concurrently with unfavourable trajectories in ALT and GGT
among participants with incident T2D.
The present work also extends previous work on the relation
between uric acid and T2D31 by showing that unfavourable
changes in uric acid precede the diagnosis of T2D in women but
not in men over a period of more than 10 years. This is in line with
results from a meta-analysis that showed that each ml dl−1 increase
in uric acid increased the risk of T2D by 28% among women but
only by 9% among men.31 This indicates that uric acid may be a
more important factor for the development of T2D in women than
men. The observed sex difference could be related to hormonal
differences. For example, uric acid levels in women have been
shown to increase due to menopause-related changes in their
metabolism32 and due to hormone replacement therapy.33 Sex
differences might also reﬂect differences in other metabolic risk
factors related to uric acid, drug use or dietary patterns.
Furthermore, although it is still uncertain whether elevated uric
acid is causally related to T2D,34 possible mechanisms include
increased oxidative stress, low-grade inﬂammation and endothelial
dysfunction, which are all related to the development of T2D.35–37
In line with our ﬁndings, the data from the Whitehall II study
and the Framingham Heart Study showed that subjects with T2D
had higher mean BMI levels than subjects without T2D at 18 and
20 years prior to diagnosis, respectively.20,38 However, we also
observed more unfavourable trajectories of BMI among those
participants who developed T2D, while the Whitehall II study
found no difference in the trajectories of BMI.20 Our ﬁndings
indicate that, independent of whether the subject is overweight,
gaining weight is important in the development of T2D.
Contrasting ﬁndings might be the result of matching on age,
Figure 1. Continued.
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sex and examination wave in our study, leading to a stricter
adjustment for age and a smaller difference in selective dropout
between those participants with and without T2D. This may have
led to trajectories of controls that were more favourable in our
study than in the Whitehall II study, and thereby to larger
differences in trajectories between those subjects with and
without T2D.
In general, the incidence of T2D is relatively low before the age
of 45 and increases exponentially thereafter, with ~ 90% of the
incident T2D cases being diagnosed after the age of 45.39–41 Since
the present study showed that the differences in trajectories of
metabolic risk factors and biochemical markers between those
with and without incident T2D start to develop more than 15–20
years before diagnosis, this indicates that measures to prevent
T2D are already warranted before the age of 25 and onwards. Our
results showed particularly unfavourable changes in adiposity,
HDL cholesterol and random glucose, and to a lesser extent in
blood pressure, triglycerides, markers of liver fat accumulation and
Table 2. Mean change in metabolic risk factors and biochemical markers over time for men with and without incident type 2 diabetes
T− 15/20 to T− 5
a T− 5 to T0
T2D No T2D T2D No T2D
Beta 95% CI Beta 95% CI Beta 95% CI Beta 95% CI
BMI (kg m− 2) 1.5 0.9 2.2 0.1 − 0.3 0.6*** − 0.4 − 0.7 − 0.03 0.1 − 0.1 0.2***
DBP (mm Hg) 2.8 − 0.2 5.7 − 0.2 − 1.8 1.4* − 3.2 − 5.0 0.9 0.6 − 0.1 1.4***
SBP (mm Hg) 5.5 0.9 10.1 1.0 − 1.4 3.4* − 1.8 − 4.7 1.0 1.2 − 0.01 2.4**
TC (mmol l− 1) − 0.1 − 0.3 0.1 0.05 − 0.1 0.2 − 0.4 − 0.5 − 0.2 0.02 − 0.04 0.1***
HDLc (mmol l− 1) − 0.09 − 0.15 − 0.03 − 0.02 − 0.06 0.02** − 0.02 − 0.06 0.02 − 0.01 − 0.02 0.02
Random glucose (mmol l− 1) 1.5 1.1 1.9 − 0.04 − 0.1 0.2*** 2.3 1.7 2.9 − 0.3 − 0.1 0.4***
WC (cm) 2.4 0.4 4.4 0.6 − 0.7 1.8** 0.03 − 1.2 1.3 0.5 − 0.2 1.2
TG (LOG mmol l− 1) 0.10 − 0.05 0.24 0.06 − 0.02 0.13 − 0.06 0.03 − 0.15 0.01 − 0.03 0.05
ALT (LOG U l− 1) 0.11 − 0.02 0.23 0.01 − 0.06 0.07 − 0.10 − 0.19 − 0.01 0.02 − 0.02 0.05**
GGT (LOG U l− 1) 0.12 − 0.004 0.25 0.05 − 0.02 0.13 − 0.07 − 0.15 0.02 0.03 − 0.01 0.08**
CRP (LOG mg l− 1) 0.22 − 0.03 0.47 0.10 − 0.05 0.26 0.09 − 0.07 0.24 0.11 0.03 0.19
UA (mmol l− 1) 0.007 − 0.011 0.026 0.005 − 0.005 0.015 − 0.035 − 0.048 − 0.023 0.002 − 0.003 0.008***
eGFR (ml min− 1/1.73 m2) 0.7 − 2.0 3.5 0.2 − 1.6 1.9 3.1 1.4 4.8 − 0.4 − 1.5 0.6***
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; GGT, gamma
glutamyltransferase; DBP, diastolic blood pressure; HDLc, high-density lipoprotein cholesterol; SBP, systolic blood pressure; T2D, type 2 diabetes; TC, total
cholesterol; TG, triglycerides; UA, uric acid; WC, waist circumference. Difference between individuals with incident type 2 diabetes and controls based on the
interaction between diabetes status and time: *Po0.10, **Po0.05, ***Po0.01. aT, time, indicating the number of years before ascertainment of type 2
diabetes or the same point in time for matched controls.
Figure 2. Trajectories of body mass index (a), systolic blood pressure (b), total cholesterol (c) and random glucose (d) of those with (solid lines)
and without (dashed lines) incident type 2 diabetes, stratiﬁed by diagnosis based on glucose ⩾ 11.1 mmol l− 1 and self-reported diabetes.
Note: time before diagnosis ranged from − 17.5 to 2.5 among the self-reported cases since participants were diagnosed somewhere between
case ascertainment (year 0) and the previous wave.
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chronic inﬂammation, uric acid and kidney function. Obesity is a
major risk factor for dyslipidaemia, hypertension, liver fat
accumulation, chronic inﬂammation and kidney dysfunction,42–45
and BMI largely explained unfavourable trajectories in those
metabolic risk factors and biochemical markers among partici-
pants with T2D. Thus, our ﬁndings highlight the need for lifestyle
interventions to promote the maintenance of a healthy weight
from young adulthood onwards to reduce the burden of T2D. Our
results further suggest that it may be of interest to investigate
whether repeated measurements of risk factors can improve risk
prediction of T2D.
One of the strengths of the present study is that, we have
measured various metabolic risk factors and biochemical markers
in a population-based cohort at four or ﬁve points in time over a
long follow-up period. We were able to describe long-term
trajectories for men and women separately. The limitations of the
present study include the limited number of participants with T2D
with a follow-up period of 15 or 20 years, leading to relatively
large 95% conﬁdence intervals for 15 and 20 years prior to case
ascertainment. We identiﬁed participants with T2D based on self-
report or random glucose levels in blood plasma. Most of these
self-reported cases were conﬁrmed by the general practitioner or
pharmacist and a validation study indicated a high level of
accuracy of self-reported diagnosis in our population.27 Never-
theless, misclassiﬁcation may have occurred, including cases not
detected by random glucose levels. As our sensitivity analyses
showed that exclusion of controls with high random glucose
levels had no effect on the results, bias is likely to be limited, and
may only have led to a small underestimation if any of the
differences in trajectories between participants with and without
incident T2D. Furthermore, individuals who participate in cohort
studies are generally healthier and better educated than non-
responders, and participants who were excluded and those who
dropped out during follow-up also had slightly less favourable
levels of the investigated risk factors at baseline. This has most
likely led to underestimation of the number of participants with
T2D and differences in trajectories between people with and
without T2D.
Our results showed that metabolic risk factors and biochemical
markers were more unfavourable in people with T2D than in
people without T2D 15–20 years or more before diagnosis of T2D
and that BMI, HDL cholesterol, random glucose and to a lesser
extent diastolic and systolic blood pressure, waist circumference,
triglycerides, liver fat and inﬂammatory markers, uric acid and
kidney function gradually deteriorate further up to diagnosis.
Unfavourable changes in these metabolic risk factors and
biochemical markers occurred at the same time and showed a
similar pattern in men and women. Differences in trajectories
between subjects with and without incident T2D were explained
largely by unfavourable changes in BMI among participants with
T2D, stressing the importance of maintaining a healthy weight.
These ﬁndings underscore the need for primary prevention that
starts more than 15 years before the diagnosis of T2D, i.e. from
young adulthood onwards.
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